Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Seres Therapeutics Q2 EPS $(2.27) Beats $(2.65) Estimate

Author: Benzinga Newsdesk | August 06, 2025 06:02am
Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(2.27) per share which beat the analyst consensus estimate of $(2.65) by 14.27 percent. This is a 47.7 percent increase over losses of $(4.34) per share from the same period last year.

Posted In: MCRB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist